Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148

Tomoya Mita,Naoto Katakami,Hidenori Yoshii,Tomio Onuma,Hideaki Kaneto,Takeshi Osonoi,Toshihiko Shiraiwa,Keisuke Kosugi,Yutaka Umayahara,Tsunehiko Yamamoto,Hiroki Yokoyama,Nobuichi Kuribayashi,Hideaki Jinnouchi,Masahiko Gosho,Iichiro Shimomura,Hirotaka Watada

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148

2017

Tomoya Mita
Naoto Katakami
Hidenori Yoshii
Tomio Onuma
Hideaki Kaneto
Takeshi Osonoi
Toshihiko Shiraiwa
Keisuke Kosugi
Yutaka Umayahara
Tsunehiko Yamamoto
Hiroki Yokoyama
Nobuichi Kuribayashi
Hideaki Jinnouchi
Masahiko Gosho
Iichiro Shimomura
Hirotaka Watada

In the Research Designand Methods section of the above-mentioned article, the measurement of carotid intima-media thickness(IMT) was described as follows: “The software systemaveraged 60 …

Keywords:

Endocrinology
Internal medicine
Alogliptin
Type 2 diabetes
Diabetes mellitus
Dipeptidyl peptidase-4 inhibitor
Medicine
Research design
in patient
carotid atherosclerosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations